Woodline Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Woodline Partners’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-617,907	Closed	-$23.7M	–	798
2023 Q2	$23.7M	Buy	+617,907	New	+$15.9M	0.28%	103
2023 Q1	–	Sell	-142,563	Closed	-$3.74M	–	871
2022 Q4	$3.74M	Sell	142,563 -166,821	-54%	-$3.7M	0.05%	364
2022 Q3	$6.08M	Sell	309,384 -91,639	-23%	-$1.84M	0.09%	264
2022 Q2	$7.01M	Buy	+401,023	New	+$6.29M	0.11%	215

Woodline Partners's KDNY Position: Q3 2023 in Review

Woodline Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 617,907 shares — an estimated $23.7M sold.

Woodline Partners first reported a position in KDNY in Q2 2022 and held it in 4 quarters. The position peaked at $23.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Woodline Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Woodline Partners sold 617,907 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $23.7M.
Woodline Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Woodline Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $23.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.